Cost effectiveness of ultrasound and bone densitometry for osteoporosis screening in post-menopausal women
Tóm tắt
According to a new German guideline, decisions about bisphosphonate treatment for post-menopausal women should be based on 10-year fracture risk, and bone density should be measured by dual x-ray absorptiometry (DXA). Recently, there has been growing interest in quantitative ultrasound (QUS) as a less expensive screening alternative. To determine the cost effectiveness of osteoporosis screening with QUS as a pre-test for DXA and treatment with alendronate compared with (i) immediate access to DXA and (ii) no screening in women of the general population aged 50-90 years in Germany. A cost-utility analysis and a budget impact analysis were performed from the perspective of the statutory health insurance (SHI). A Markov model with a 1-year cycle length was used to simulate costs and benefits (QALYs), discounted at 3% per annum, over a lifetime. The number of women correctly diagnosed by QUS and DXA as being above a 10-year risk of ≥30% was estimated for different age groups (50–60, 60–70, 70–80 and 80–90 years, respectively). The robustness of the results was tested by a probabilistic Monte Carlo simulation. Compared with no screening, the cost effectiveness of QUS plus DXA was found to be €3529, €9983, €4382 and €1987 per QALY for 50-, 60-, 70- and 80-year-old women, respectively (year 2006 values). This screening strategy results in annual costs of €96 million or 0.07% of the SHI’s annual budget. The cost effectiveness of DXA alone compared with DXA plus QUS is €5331, €60 804, €14943 and €3654 per QALY for 50-, 60-, 70- and 80-year-old women, respectively. DXA alone results in a higher number of QALYs in all age groups. The results were robust in the sensitivity analysis. Compared with no screening, the cost effectiveness of QUS and DXA in sequence is very favourable in all age groups. However, direct access to DXA is also a cost-effective option, as it increases the number of QALYs at an acceptable cost compared with pre-testing by QUS (except for women aged 60–70 years). Therefore, QUS as a pre-test for DXA can be clearly recommended only in women aged 60–70 years. For the other age groups, the cost effectiveness of QUS as a pre-test depends on the global budget constraint and the accessibility of DXA.
Tài liệu tham khảo
Ribot C, Tremollieres F, Pouilles JM. Can we detect women with low bone mass using clinical risk factors? Am J Med 1995 Feb 27; 98(2A): 52S–5S
Häussler B, Gothe H, Göl D. Epidemiology, and costs of osteoporosis in Germany: the boneEVA study. Osteoporosis Int 2007; 18: 77–84
Weyler EJ, Gandjour A. Socioeconomic burden of hip fractures in Germany. Gesundheitswesen 2007; 69(11): 601–6
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry. JAMA 2002; 288(15): 1889–97
WHO Study Group. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843: 1–129
Federal Joint Commitee (GBA). Osteodensitometrie. Zusammenfassender Bericht des Arbeitsausschusses “Ärztliche Behandlung” des Bundesausschusses der Ärzte und Krankenkassen über die Beratungen des Jahres 1999 zur Bewertung der Osteodensitometrie gemäߧ135 Abs. 1 SGB V (2000) [online]. Available from URL: http://www.g-ba.de [Accessed 2008 Oct 7]
National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008 [online]. Available from URL: http://www.nof.org [Accessed 2008 Apr 21]
Kanis JA, Delmas PD, Burckhardt P, et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporosis Int 1997; 7: 390–406
Marshall D, Johnell O, Wedel H, et al. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–9
Kanis JA, Johnell O, Oden A, et al. 10-year risk of osteo-porotic fracture and the effect of risk factors on screening strategies. Bone 2002; 30(1): 251–8
World Health Organization (WHO). FRAX: WHO fracture risk assessment tool [online]. Available from URL: http://www.shef.ac.uk [Accessed 2008 Apr 21]
German osteology umbrella organization, DVO. Prophylaxe, Diagnostik und Therapie der Osteoporose. S3-Leitlinie des Dachverbandes der deutschsprachigen wissenschaftlichen osteologischen Gesellschaften (2006) [online]. Available from URL: http://www.lutherhaus.de [Accessed 2008 Oct 7]
Müller D, Weyler EJ, Gandjour A. Cost-effectiveness of post-menopausal osteoporosis screening and treatment based on 10-year fracture risk. Pharmacoeconomics 2008; 26(6): 513–36
Hans D, Dargent-Molina P, Schott AM, et al. Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996; 348: 511–4
Lewiecki EM, Richmond B, Miller PD. Uses and misuses of quantitative ultrasonography in managing osteoporosis. Cleve Clin J Med 2006; 73(8): 742–6, 749-52
Huopio J, Kroger H, Honkanen R, et al. Calcaneal ultrasound predicts early post-menopausal fractures as well as axial BMD: a prospective study of 422 women. Osteoporosis Int 2004; 15(3): 190–5
Khaw PK, Reeve J, Luben R, et al. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus. Lancet 2004; 363(9404): 197–202
Nayak S, Olkin I, Liu H, et al. Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis. Ann Intern Med 2006; 144: 832–41
Marin F, Gonzales-Macias J, Diez-Perez A, et al. Relationship between bone quantitative ultrasound and fractures: a meta-analysis. J Bone Mine Res 2006 Jul; 21(7): 1126–35
US Preventive Services Task Force. Screening for osteoporosis in post-menopausal women: recommendations and rationale. 2002 Sep [online]. Available from URL: http://www.ahrq.gov [Accessed 2007 Jun 12]
Kanis JA, Johnell O, Zethraeus, et al. Intervention thresholds for osteoporosis in the UK. Bone 2005; 36: 22–32
Kanis JA, Johnell O, Oden A, et al. Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporosis Int 2005; 16: 6–14
van Staa TP, Kanis JA, Geusens P. The cost-effectiveness of bisphosphonates in post-menopausal women based on individual long-term fracture risks. Value Health 2007 Sep-Oct; 10(5): 348–57
Bundeszentrale für politische Bildung (bpb). Krankenversicherungsschutz der Bevölkerung (2003) [online]. Available from URL: http://www.bpb.de [Accessed 2007 Feb 13]
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Statist Med 2004; 23: 3105–24
Federal Statistical Office Germany (DESTATIS). Sterbefälle 2005/2007 [online]. Available from URL: http://www.destatis.de [Accessed 2008 Oct 7]
Kanis JA, Johnell O, DeLaet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2005; 35: 375–82
Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007; 297(4): 387–94
Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 16; 276(15): 1253–8
Federal Statistical Office Germany (DESTATIS). Consumer Price Index for Germany (2006) [online]. Available from URL: http://www.destatis.de [Accessed 2008 Oct 7]
Tosteson ANA, Jönsson B, Grima DT, et al. Challenges for model-based economic evaluations of post-menopausal osteoporosis interventions. Osteoporosis Int 2001; 12: 849–57
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alen-dronate on bone mineral density and the incidence of fractures in post-menopausal osteoporosis. The Alen-dronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437–43
Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535–41
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 80: 2077–82
Greenland S, Robbins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985; 41: 55–68
Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006; 144: 753–61
Black DM, Schwartz AV, Ensrud KE. Effects ofcontinuing or stopping alendronate after 5 years of treatment. The Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006 Dec 27; 296(24): 2927–38
O’Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women. The European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11(7): 1010–8
van der Klift M, DeLaet CE. The incidence of vertebral fractures in men and women: The Rotterdam Study. J Bone Miner Res 2002; 17(6): 1051–6
Federal Statistical Office Germany (DESTATIS). Diagnosedaten der Krankenhauspatientinnen und -patienten (einschließlich Sterbe- und Stundenfälle) (2006) [online]. Available from URL: https://www-ec.destatis.de/csp/shop/sfg/bpm.html.cms.cBroker.cls?cmspath=struktur,Warenkorb.csp&action=basketadd&id=1021733 [Accessed 2008 Oct 7]
Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17(4): 716–23
Singer BR, McLauchlan GJ, Robinson CM, et al. Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 1998; 80: 243–8
Melton LJ, Thamer M, Ray NF, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12(1): 16–23
De Laet C, Oden A, Johansson H, et al. The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporosis Int 2005; 16: 313–8
Federal Statistical Office Germany (DESTATIS). Bevölk-erung nach Altersgruppen, Deutschland (2004) [online]. Available from URL: http://www.destatis.de [Accessed 2008 Oct 7]
Browner WS, Seeley DG, Vogt TM, et al. Non-trauma mortality in elderly women with low bone mineral density. Lancet 1991; 33810: 355–8
Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 872–82
Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women. Arch Intern Med 1999; 159: 1215–20
Gandjour A, Weyler EJ. Cost-effectiveness of referrals to high-volume hospitals: an analysis based on a probabilistic Markov model for hip fracture surgeries. Health Care Manage Sci 2006; 9: 359–69
Brazier JE, Green C, Kanis JA. A systematic review of health state utility values for osteoporosis-related conditions. Osteoporosis Int 2002; 13: 768–76
Kanis JA, Johnell O, Oden A. The risk and burden of vertebral fractures in Sweden. Osteoporosis Int 2004; 15: 20–6
Schousboe JT, Ensrud KE, Nyman JA, et al. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. J Am Geriatr Soc 2005; 53: 1697–170
Deeks JJ. Using evaluations of diagnostic tests: understanding their limitations and making the most of available evidence. Annals of Oncology 1999; 10: 761–8
Greenhalgh T. How to read a paper: papers that report diagnostic or screening tests. BMJ 1997; 315(7107): 540–3
Valenstein PN. Evaluating diagnostic tests with imperfect standards. Am J Clin Pathol 1990; 93: 252–8
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM). Kreuzschmerzen (2003) [online]. Available from URL: http://www.degam.de [Accessed 2006 Jun 14]
Neuhauser H, Ellert U, Ziese T. Chronic back pain in the general population in Germany 2002/2003: prevalence and highly affected population groups. Gesundheitswesen 2005; 67(10): 685–93
PMV Research Group. Versorgungssituation von Patienten mit chronisch lumbalen Rückenschmerzen [online]. Available from URL: http://www.pmvforschungsgruppe.de [Accessed 2006 Dec 12]
Cooper C, Atkinson EJ, O’Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota 1985-1989. J Bone Miner Res 1992; 7: 221–7
Delmas PD, van de Langerijt L, Watts NB, et al. Under-diagnosis ofvertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005; 20(4): 557–63
National Osteoporosis Foundation (NOF). Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporosis Int 1998; 8 Suppl. 4: 7–80
Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med 1995; 332: 767–73
Cadarette SM, Jaglal SB, Murray TM, et al. Evaluation of decision rules of referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001; 286(1): 57–63
Federal Statistical Federal Statistical Office Germany (DE-STATIS). Krankheitskosten 2002, 2004 und 2006 [online]. Available from URL: https://www-ec.destatis.de/csp/shop/sfg/bpm.html.cms.cBroker.cls?cmspath=struktur,Warenkorb.csp&action=basketadd&id=1022497 [Accessed 2008 Oct 7]
Kassenärztliche Bundesvereinigung. Uniform Value Scale (2006) [online]. Available from URL: http://www.ebm2000plus.de [Accessed 2008 Oct 7]
Ärztekammer. German medical fee schedule (GOÄ 2006) [online]. Available from URL: http://www.e-bis.de [Accessed 2007 Dec 12]
Rote Liste Service GmbH. German red list (2006) [online]. Available from URL: http://www.rote-liste.de [Accessed 2006 Jun 9]
Zentralinstitut für Kassenärztliche Versorgung. ZI_ADT-anel Nordrhein, Patienten-/Praxisstichprobe: IV/2005 [online]. Available from URL: http://www.zi-berlin.de [Accessed 2006 Jun 13]
Physio.de Informationsdienste GmbH. Catalogue of non-physician treatments (2004) [online]. Available from URL: http://www.heilmittelkatalog.de [Accessed 2006 May 19]
Physio.de Informationsdienste GmbH. Price lists (2004) [online]. Available from URL: http://www.physio.de [Accessed 2006 May 19]
Institut für das Entgeltsystem im Krankenhaus (InEK). Fallpauschalenkatalog (2006) [online]. Available fromURL: http://www.g-drg.de [Accessed 2008 Oct 7]
Institut für das Entgeltsystem im Krankenhaus (InEK). Abschlussbericht zur Weiterentwicklung des G-DRG-Systems für das Jahr 2004. Klassifikation, Katalog und Bewertungsrelationen. Band II: Fallpauschalenkatalog, klinische Profile, Kostenprofile [online]. Available from URL: http://www.g-drg.de [Accessed 2008 Oct 7]
Wikipedia. Diagnosis-related group [online]. Available from URL: http://en.wikipedia.org [Accessed 2008 Apr 19]
Melo M, Qiu F, Sykora K, et al. Persistence with bisphos-phonate therapy in older people. J Am Geriatr Soc 2006; 54(6): 1015–6
Bartl R, Götte S, Hadji P, et al. Adherence with daily and eekly administration of oral bisphosphonates for osteoporosis. Dtsch Med Wochenschr 2006; 131: 1257–62
Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimes among women with post-menopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453–60
Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with post-menopausal osteoporosis. Clin Ther 2006; 28(2): 236–42
Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology: the essentials. 3rd ed. Baltimore (MD): Williams & Wilkins, 1996
Frybeck DG, Chinnis JO, Ulvila JW. Bayesian cost effectiveness analysis: an example using the GUSTO trial. Int J Technol Assess Health Care 2001; 17(1): 83–97
Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Dec Making 1998; 18 Suppl.: S65–80
van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3: 309–19
Federal Statistical Office Germany (DESTATIS). Health expenditures by sources of funding [online]. Available from URL: http://www.gbe-bund.de [Accessed 2008 Oct 7]
Weinstein MC. Principles of cost-effective resource allocation in health care organisations. Int J Technol Assess Health Care 1990; 6(1): 93–103
Gandjour A, Stock S. A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 2007 Oct; 83(2-3): 257–67
Begg CB. Biases in the assessment of diagnostic tests. Stat Med 1987; 6(4): 411–23
Harris ST, Watts NB, Genant HK, et al. Effects of rise-dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Rise-dronate Therapy (VERT) Study Group. JAMA 1999; 282(14): 1344–52
De Laet C, van Hout B, Burger H, et al. Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporosis Int 1999; 10: 66–72
Stevenson M, Lloyd Jones M, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of post-menopausal osteoporosis. Health Technol Assess 2005; 2005 Jun; 9(22): 1–160
Schousboe JT. Cost-effectiveness modeling research of pharmacologic therapy to prevent osteoporosis-related fractures. Curr Rheumatol Rep 2007 Apr; 9(1): 50–6
Sim MF, Stone MD, Phillips CJ, et al. Cost effectiveness analysis of using quantitative ultrasound as a selective pre-screen for bone densitometry. Technol Health Care 2005; 13(2): 75–85
Marin F, López-Bastida J, Diez-Pérez A, et al. Bone mineral density referral for dual-energy X-ray absorptiometry using quantitative ultrasound as a prescreening tool in post-menopausal women from the general population: a cost-effectiveness analysis. Calcif Tissue Int 2004; 74(3): 277–83
Kraemer DF, Nelson HD, Bauer DC, et al. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women. Osteoporosis Int 2006; 17(1): 68–76
Federal Statistical Office Germany (DESTATIS). Employment [online]. Available from URL: http://www.destatis.de [Accessed 2008 Oct 7]
Kanis JA, Borgstrom F, DeLaet C, et al. Assessment of fracture risk. Osteoporosis Int 2005; 16: 581–9